Novo Nordisk's Mim8 prophylaxis switching from emicizumab well-tolerated with no safety concerns or events.

From GlobeNewswire: 2025-06-22 15:35:00

Novo Nordisk presented data from the FRONTIER5 trial showing that a switch to investigational Mim8 prophylaxis from emicizumab was well-tolerated in adults and adolescents with hemophilia A. Patients reported a strong preference for the Mim8 pen-injector over their previous system. This switch led to increased thrombin levels without posing a thrombotic risk. The trial included 61 participants and found no safety concerns or adverse events. The results were presented at the ISTH Congress in Washington, D.C. Novo Nordisk plans to submit Mim8 for regulatory review in 2025, with ongoing data from the FRONTIER program to be disclosed later.



Read more at GlobeNewswire: Mim8 prophylaxis treatment shown to be